TNGX Earnings Date: Nov 3, 2026 (Estimated) — Tango Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is TNGX's next earnings date?
Tango Therapeutics, Inc. (TNGX) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.35 on revenue of $3.3M.
How did TNGX do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Tango Therapeutics, Inc. posted EPS of -$0.37 versus the -$0.32 estimate, a miss of 15.6%. Revenue was $0 against a $1.6M estimate. The stock's 1-day post-earnings move was -4.8%.
How much does TNGX stock move after earnings?
TNGX beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.6% (up or down) in the day after earnings.
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.32 | -0.37 | -15.62% | $0 | ❌ Miss | -4.81% | -8.60% | -13.26% |
| 2026-08-10 | -0.32 | -0.37 | -16.65% | — | ❌ Miss | -2.70% | -5.43% | -16.14% | |
| 2026-05-13 | Q1 2026 | -0.32 | -0.32 | +0.00% | $0 | ➖ Inline | -2.51% | -17.37% | +21.29% |
| 2026-03-05 | Q4 2025 | -0.32 | -0.29 | +9.38% | $0 | ✅ Beat | +36.28% | +37.57% | +75.14% |
| 2025-11-04 | Q3 2025 | -0.04 | 0.14 | +450.00% | $53.8M | ✅ Beat | +0.00% | -1.00% | +19.48% |
| 2025-08-05 | Q2 2025 | -0.35 | -0.35 | +0.00% | $3.2M | ➖ Inline | +4.86% | -2.73% | +1.67% |
| 2025-02-27 | Q4 2024 | -0.34 | -0.35 | -2.94% | $4.1M | ❌ Miss | -6.44% | -10.30% | -30.90% |
| 2024-08-07 | Q2 2024 | -0.34 | -0.24 | +29.41% | $19.9M | ✅ Beat | -3.22% | +0.44% | +29.63% |
Showing last 8 quarters.